AstraZeneca, Daiichi Sankyo HER2 Breast Cancer Drug Wins Ninth China Indication

The significance here is less the molecule than the pattern: a single antibody-drug conjugate is being stretched across an expanding set of treatment settings in China, and the adjuvant label moves it earlier in the patient journey, where volumes are structurally larger than in later-line use. That matters for AstraZeneca and Daiichi Sankyo's China franchise and for the competitive positioning of rival HER2 agents. The open question is whether this indication cadence keeps compounding, and how quickly the adjuvant setting is adopted in practice.